Pyridoxine and pyridostigmine treatment in vincristine-induced neuropathy.
Vincristine is a commonly used antineoplastic drug and frequently causes neurotoxicity. Here the authors report a 4-year-old boy with acute lymphoblastic leukemia in whom vincristine-induced peripheral and cranial neuropathy developed during remission induction therapy. The patient seemed to benefit from pyridoxine and pyridostigmine therapy greatly and this therapy is recommended in patients with severe vincristine-induced neuropathy.
Ozyurek
Hamit
H
Ondokuz Mayis University, Faculty of Medicine, Department of Pediatrics, Section of Neurology, Samsun, Turkey. hozyurekibu@hotmail.com
Turker
Hande
H
Akbalik
Mehtap
M
Bayrak
Ayse Oytun
AO
Ince
Hulya
H
Duru
Feride
F
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001370:Axonal Transport / Q000187:drug effects; D001763:Blepharoptosis / Q000139:chemically induced / Q000188:drug therapy; D002675:Child, Preschool; D002800:Cholinesterase Inhibitors / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D016371:Cranial Irradiation; D003389:Cranial Nerve Diseases / Q000139:chemically induced / Q000188:drug therapy*; D004830:Epilepsy, Tonic-Clonic / Q000139:chemically induced; D020233:Gait Disorders, Neurologic / Q000139:chemically induced / Q000188:drug therapy; D006323:Heart Arrest / Q000139:chemically induced / Q000628:therapy; D006801:Humans; D008297:Male; D018696:Neuroprotective Agents / Q000627:therapeutic use*; D010523:Peripheral Nervous System Diseases / Q000139:chemically induced / Q000188:drug therapy*; D015452:Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / Q000150:complications / Q000188:drug therapy* / Q000532:radiotherapy; D011729:Pyridostigmine Bromide / Q000627:therapeutic use*; D011736:Pyridoxine / Q000627:therapeutic use*; D012678:Sensation Disorders / Q000139:chemically induced / Q000188:drug therapy; D014474:Unconsciousness / Q000139:chemically induced; D014750:Vincristine / Q000008:administration & dosage / Q000009:adverse effects*
D002800:Cholinesterase Inhibitors; D018696:Neuroprotective Agents; D014750:Vincristine; D011736:Pyridoxine; D011729:Pyridostigmine Bromide